Suppr超能文献

[ST段抬高型心肌梗死的溶栓治疗。基于近期研究的当前作用]

[Thrombolysis in ST-elevation myocardial infarction. Current role in the light of recent studies].

作者信息

Arntz H-R, Zeymer U, Schwimmbeck P

机构信息

Med. Klinik II, Kardiologie/Pulmologie, Charité, Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin.

出版信息

Anaesthesist. 2004 May;53(5):445-54. doi: 10.1007/s00101-004-0678-0.

Abstract

As acute percutaneous interventions are only performed in about 20% of patients in Germany, thrombolysis will continue to play an essential role in the treatment of ST-elevation infarction. There is no real alternative to thrombolysis in hospitals without catheter facilities or with long transport times, especially for patients with a short duration of symptoms. Prehospital thrombolysis is widely underused despite its proven efficacy and safety. This is especially the case with respect to mortality of patients with symptoms <3 h, where thrombolysis seems to be at least as effective as or even superior to percutaneous coronary intervention (PCI) with respect to mortality (most probably by avoiding cardiogenic shock). "Facilitated PCI", i.e. thrombolysis +/-Gp IIb/IIIa receptor blocker and consecutive routine PCI is attractive and may be an option for the future. However, the logistic burden and problems of availability of EMS have not yet been investigated. Also, the principal value of "rescue PCI"still needs to be clarified. Moreover, defining simple clinical parameters which help to detect ineffective thrombolysis as well as time windows for detection and consecutive rescue intervention are urgent tasks for the near future. In order to guarantee an optimized and individualized therapy for the patient with acute myocardial infarction, peripheral hospitals, intervention centres and emergency medical services should set up networks, which consider the local resources, time lines and the specific conditions of the patient.

摘要

在德国,仅约20%的患者会接受急性经皮介入治疗,因此溶栓治疗在ST段抬高型心肌梗死的治疗中仍将发挥重要作用。对于没有导管设备或转运时间较长的医院,尤其是症状持续时间较短的患者,溶栓治疗没有真正的替代方案。尽管院前溶栓已证实其有效性和安全性,但仍未得到充分应用。对于症状出现<3小时的患者的死亡率而言,情况尤其如此,在死亡率方面(很可能是通过避免心源性休克),溶栓治疗似乎至少与经皮冠状动脉介入治疗(PCI)一样有效,甚至更优。“易化PCI”,即溶栓治疗+/-糖蛋白IIb/IIIa受体阻滞剂及随后的常规PCI很有吸引力,可能是未来的一种选择。然而,紧急医疗服务的后勤负担和可用性问题尚未得到研究。此外,“补救性PCI”的主要价值仍需阐明。此外,确定有助于检测无效溶栓的简单临床参数以及检测和随后补救干预的时间窗是近期的紧迫任务。为了确保为急性心肌梗死患者提供优化的个体化治疗,周边医院、介入中心和紧急医疗服务机构应建立网络,综合考虑当地资源、时间安排和患者的具体情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验